Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 18;78(5):1017–1027. doi: 10.1016/j.jhep.2023.02.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — Similar breadth of the spike-specific CD4+ T-cell epitope repertoire in LTRs and HCs after mRNA vaccination.

(A) Numbers of CD4+ T-cell responses to spike-OLP after in vitro expansion per individual after the 3^rd (HCs n = 9; LTRs n = 9) vaccine dose. (B) Number and location of spike-specific CD4+ T-cell responses to spike-OLP after in vitro expansion in HCs vs. LTRs after the 3^rd vaccine dose, numbers of tested individuals (per HLA allotype and in total) are indicated. OLP with > 1 HLA-matched previously described epitopes are crosshatched. (C) Numbers of CD4+ T-cell responses to spike-OLP after in vitro expansion per individual tested longitudinally in LTRs after the 2^nd (n = 8), 3^rd (n = 8) and 4^th (n = 3) mRNA vaccine dose. (D) Number and location of CD4+ T-cell responses to spike-OLP after in vitro expansion in LTRs (n = 3) tested longitudinally after the 2^nd, 3^rd and 4^th mRNA vaccine dose. (E-G) Ex vivo frequencies of AIM+ (CD137+ OX40+) CD4+ T cells after the 3^rd mRNA vaccine dose (E, HCs n = 14, LTRs n = 14) with representative plots (F) and tested longitudinally after the 2^nd (n = 7) and 3^rd (n = 7) mRNA vaccine dose (G). Statistics: Mann-Whitney U test (A, E) and Wilcoxon matched-pairs signed rank test (C, G). HCs, healthy controls; LTRs, liver transplant recipients; OLP, overlapping peptide.